Japan Benign Prostate Hyperplasia Drugs Market was valued at USD 0.9 Billion in 2022 and is projected to reach USD 1.4 Billion by 2030, growing at a CAGR of 6.8% from 2024 to 2030.
Japan's benign prostatic hyperplasia (BPH) drug market has undergone significant transformations in recent years, influenced by demographic shifts, evolving healthcare policies, and changing prescribing patterns. BPH, a non-cancerous enlargement of the prostate gland, affects a substantial portion of the male population, leading to various urinary symptoms and impacting quality of life.
**Market Overview and Trends**
Between 2014 and 2021, Japan witnessed an increase in prescriptions for α1-blockers, rising from 9,898 per 1,000 males in 2014 to 12,613 in 2021. Similarly, prescriptions for 5α-reductase inhibitors grew from 1,441 to 2,310 per 1,000 males during the same period. Phosphodiesterase type 5 inhibitors, notably tadalafil, also saw a surge in prescriptions, from 900 in 2015 to 2,520 in 2021. However, despite these increases, the overall market size for BPH drugs declined from $664 million in 2014 to $279 million in 2021. This decline is largely attributed to a shift towards generic medications and government-imposed price adjustments aimed at controlling healthcare costs. citeturn0search0
**Therapeutic Classes and Prescribing Patterns**
The primary therapeutic classes for BPH in Japan include α1-blockers, 5α-reductase inhibitors, and phosphodiesterase type 5 inhibitors. α1-blockers function by relaxing prostate and bladder neck muscles, facilitating urine flow. 5α-reductase inhibitors address prostate enlargement by inhibiting the conversion of testosterone to dihydrotestosterone. Phosphodiesterase type 5 inhibitors, such as tadalafil, not only treat erectile dysfunction but also alleviate BPH symptoms by relaxing smooth muscles in the prostate and bladder.
**Impact of Healthcare Policies**
Japan's healthcare policies have significantly influenced the BPH drug market. The government's efforts to reduce pharmaceutical expenditures have led to price reductions and a promotion of generic drug usage. While these measures have helped control costs, they have also contributed to the market's contraction, as patients increasingly opt for more affordable generic options over brand-name drugs.
**Future Outlook**
Looking ahead, the demand for BPH medications in Japan is expected to persist, driven by the aging population and a continued focus on managing BPH symptoms effectively. However, market growth may be tempered by ongoing healthcare reforms and a preference for generic drugs. Pharmaceutical companies may need to innovate and adapt their strategies, focusing on value-added formulations and patient-centric services to maintain market share in this evolving landscape.
Get an In-Depth Research Analysis of the Japan Benign Prostate Hyperplasia Drugs Market Size And Forecast [2025-2032]
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Benign Prostate Hyperplasia Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Benign Prostate Hyperplasia Drugs Market
Alpha-Blockers
5-Alpha Reductase Inhibitors
Combination Therapies
Oral Medications
Injected Medications
Topical Medications
Age Groups
Gender
Severity of Symptoms
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Wholesalers
Hospitals
Specialty Clinics
Home Care Settings
Long-term Care Facilities
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Benign Prostate Hyperplasia Drugs Market Research Analysis
1. Introduction of the Japan Benign Prostate Hyperplasia Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Benign Prostate Hyperplasia Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Benign Prostate Hyperplasia Drugs Market, By Type
6. Japan Benign Prostate Hyperplasia Drugs Market, By Application
7. Japan Benign Prostate Hyperplasia Drugs Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Benign Prostate Hyperplasia Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/